Enclomiphene vs Testosterone: Mechanism and Class Compared

Enclomiphene and testosterone sit in two entirely different pharmacological classes. Enclomiphene citrate is a selective estrogen receptor modulator (SERM) — specifically the trans-stereoisomer of clomiphene citrate — that acts upstream on the hypothalamic–pituitary axis. Testosterone is the endogenous androgen itself, and testosterone products are hormone replacements that supply the hormone from outside the body. Understanding the difference matters because the two produce opposite effects on the pituitary signal even when serum testosterone moves in the same direction. This page is for educational purposes only and is not medical advice; consult a licensed physician about any question concerning diagnosis, suitability or treatment.

Is Enclomiphene a Testosterone?

No. Enclomiphene contains no steroid nucleus. It is a triphenylethylene compound, structurally related to tamoxifen and clomiphene, and it was characterised in the pharmacology literature as an estrogen receptor antagonist developed for testosterone deficiency in men (PMID 19204885). Testosterone, by contrast, is a C19 steroid that binds the androgen receptor directly.

The confusion is understandable: both have been studied in men with low serum testosterone, and both have been reported to raise serum testosterone concentrations. A randomised phase II trial compared oral enclomiphene citrate with topical testosterone in men with secondary hypogonadism and reported that enclomiphene raised testosterone while preventing the fall in sperm counts seen with the topical androgen (PMID 25044085). Reaching a similar endpoint by a different route is not the same as belonging to the same drug class.

Mechanism: Upstream Modulation Versus Direct Replacement

How enclomiphene was described to work

Estradiol, derived from testosterone by aromatase, exerts negative feedback on the hypothalamus and pituitary. Enclomiphene occupies estrogen receptors at those sites, so the feedback signal is interrupted and gonadotropin-releasing hormone, luteinising hormone (LH) and follicle-stimulating hormone (FSH) output rises. Pharmacodynamic and pharmacokinetic work in men with secondary hypogonadism reported that oral enclomiphene citrate increased LH, FSH and total testosterone (PMID 23875626). A review of enclomiphene citrate for secondary male hypogonadism summarised the same upstream mechanism, describing the agent as restoring testosterone through the patient's own Leydig cells rather than supplying hormone externally (PMID 27337642).

Because the pathway runs through LH and the testes, an intact hypothalamic–pituitary–gonadal axis and functioning Leydig cells are prerequisites. A review of Leydig stem cells and future hypogonadism therapies placed stimulatory approaches such as SERMs alongside replacement in the broader treatment landscape, noting that each depends on different assumptions about testicular capacity (PMID 33003069).

How testosterone products work

Exogenous testosterone binds the androgen receptor in target tissues directly and does not require pituitary signalling. The consequence is the mirror image of the SERM mechanism: the added androgen and its aromatised estradiol strengthen negative feedback, LH and FSH fall, and intratesticular testosterone — the high local concentration that spermatogenesis depends on — declines. A review of strategies for preserving spermatogenesis in testosterone deficiency set out this distinction between replacement and stimulatory therapies and the fertility implications attached to each (PMID 41522318).

Side-by-Side: Class Features

What the Comparative Trials Reported

Two published comparisons placed oral enclomiphene citrate against transdermal testosterone in men with low testosterone. One reported that oral enclomiphene citrate stimulated endogenous testosterone production and sperm counts, with the testosterone gel comparator serving as the reference arm (PMID 23530575). The randomised phase II trial reported that enclomiphene raised testosterone while preventing oligospermia, which the gel arm did not (PMID 25044085).

These are the key mechanistic signatures separating the classes: a drug working through the pituitary carries gonadotropins upward with it, while a drug supplying hormone from outside does not. Researchers summarising the agent in a dedicated review framed enclomiphene citrate as a treatment that maintains fertility in men with secondary hypogonadism, tying that property directly to its upstream site of action (PMID 31063005).

Evidence synthesis has also been attempted. A 2025 systematic review and meta-analysis of randomised controlled trials examined clomiphene or enclomiphene citrate for male hypogonadism and pooled the available randomised data (PMID 41066380). A 2024 review of the safety and efficacy of enclomiphene and clomiphene in hypogonadal men covered the same territory from a narrative angle (PMID 39434750). A clinical inquiry in the family medicine literature asked whether SERMs are safe and effective for hypogonadism in men and reviewed the evidence base available at the time (PMID 35259334). This page summarises what those publications reported; it does not weigh them into a recommendation, and no comparison here should be read as indicating which option suits any individual.

Why the Isomer Distinction Exists

Clomiphene citrate is a mixture of two geometric isomers: enclomiphene (trans) and zuclomiphene (cis). They differ in receptor behaviour and in persistence. A study measuring serum levels of enclomiphene and zuclomiphene in men with hypogonadism on long-term clomiphene citrate treatment reported that the two isomers accumulated differently during chronic dosing (PMID 27511863). That observation is the pharmacological rationale behind isolating the trans-isomer, and it is also why enclomiphene and clomiphene — though frequently reviewed together, as in the 2024 safety and efficacy review (PMID 39434750) — are not interchangeable terms.

Neither isomer is an androgen. Both are estrogen receptor ligands, which keeps the whole clomiphene family on the opposite side of the mechanistic divide from testosterone.

Regulatory Status

Testosterone products are approved prescription medicines in the United States and many other jurisdictions, dispensed under prescription and, in the US, scheduled as controlled substances. Enclomiphene citrate is a prescription medicine; it has been studied in randomised clinical trials for secondary male hypogonadism and the published literature describes it as an investigational agent in that indication, with review articles cataloguing its development history (PMID 19204885) and its clinical evaluation (PMID 27337642). Clomiphene citrate, the isomer mixture, holds approval for ovulation induction in women; its use in men has been discussed in the hypogonadism literature (PMID 41066380). Approval status differs by country and changes over time, and a prescribing clinician or national regulator is the appropriate source for current status.

This page does not state doses for either agent. Dose selection, candidacy, monitoring and the decision to pursue any therapy are clinical matters determined by a prescribing clinician in the context of an individual's laboratory results and history.

Adverse Events: What Studies Report

Published safety summaries treat the two classes separately because their adverse-event profiles follow their mechanisms. A 2024 review assessed the safety and efficacy of enclomiphene and clomiphene for hypogonadal men and discussed tolerability alongside efficacy outcomes (PMID 39434750). The 2025 systematic review and meta-analysis of randomised controlled trials also addressed safety outcomes across the pooled trials (PMID 41066380), and the family practice clinical inquiry evaluated whether SERMs were safe and effective in this population (PMID 35259334). For testosterone replacement, the spermatogenesis-focused review described suppression of the gonadotropin axis as an expected consequence of exogenous androgen and the reason stimulatory alternatives have been investigated (PMID 41522318). Anyone seeking a risk assessment for their own circumstances should obtain it from a licensed physician.

Key Takeaways

• Enclomiphene is a SERM, not an androgen; testosterone is the androgen hormone itself.
• Enclomiphene acts at estrogen receptors in the hypothalamus and pituitary; testosterone acts at androgen receptors in target tissues (PMID 19204885).
• Trials reported that enclomiphene raised LH, FSH and testosterone (PMID 23875626), while the comparator gel arms did not share that gonadotropin pattern (PMID 25044085).
• Enclomiphene is the trans-isomer of clomiphene, and the isomers behave differently in serum during long-term treatment (PMID 27511863).
• Both are prescription medicines; regulatory status varies by jurisdiction and by indication.

For a fuller overview of the compound itself, see the enclomiphene learn page at /learn/enclomiphene/.

References

• Safety and efficacy of enclomiphene and clomiphene for hypogonadal men (Translational Andrology and Urology, 2024)
• Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men (IDrugs, 2009)
• Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials (Archives of Endocrinology and Metabolism, 2025)
• Enclomiphene citrate for the treatment of secondary male hypogonadism (Expert Opinion on Pharmacotherapy, 2016)
• Leydig stem cells and future therapies for hypogonadism (Current Opinion in Endocrinology, Diabetes and Obesity, 2020)
• Enclomiphene citrate: A treatment that maintains fertility in men with secondary hypogonadism (Expert Review of Endocrinology & Metabolism, 2019)
• Are SERMs safe and effective for the treatment of hypogonadism in men? (The Journal of Family Practice, 2022)
• Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics (BJU International, 2013)
• Preserving spermatogenesis in testosterone deficiency: innovations in replacement and stimulatory therapies (Translational Andrology and Urology, 2025)
• Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone (Fertility and Sterility, 2014)
• Serum levels of enclomiphene and zuclomiphene in men with hypogonadism on long-term clomiphene citrate treatment (BJU International, 2017)
• Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel (The Journal of Sexual Medicine, 2013)